Oncology and Hematology

81-96 of 141

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers

  Sara Lonardi, MD; Aparna R. Parikh, MD

  1.25 credits 10 episodes

  • 

    

    Sara Lonardi, MD

  • 

    

    Aparna R. Parikh, MD

  • 

    

    Alan Venook, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  MinuteCE®

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  William J. Gradishar, MD; Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  MinuteCE®

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  MinuteCE®

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence     

  RestartResume

  Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence     

  MinuteCE®

  Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence     

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  RestartResume

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  MinuteCE®

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  Alan Venook, MD

  1.25 program credits

  • 

    

    Alan Venook, MD

  1.25 program credits

• 

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  MinuteCE®

  Management of HER2-Low MBC Following First-Line Disease Progression

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  MinuteCE®

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  RestartResume

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  MinuteCE®

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  William J. Gradishar, MD

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  1.50 program credits

• 

  RestartResume

  Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

  RestartResume

  Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

  MinuteCE®

  Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

  Alan Venook, MD

  1.25 program credits

  • 

    

    Alan Venook, MD

  1.25 program credits

• 

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  MinuteCE®

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  MinuteCE®

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Emerging Treatment Approaches for EBC

  RestartResume

  Emerging Treatment Approaches for EBC

  MinuteCE®

  Emerging Treatment Approaches for EBC

  William J. Gradishar, MD

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  1.50 program credits

• 

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  MinuteCE®

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  MinuteCE®

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  MinuteCE®

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• Previous
• 1
• 2
• …
• 4
• 5
• 6
• 7
• 8
• 9
• Next